Medication
Colyte
DIN 00677442 · Pendopharm Division of Pharmascience Inc
What it is
- Active ingredients
- Polyethylene Glycol 3350 — 857.69 mg
- Sodium Chloride — 20.87 mg
- Potassium Chloride — 10.65 mg
- Sodium Bicarbonate — 24.02 mg
- Sodium Sulfate — 81.2 mg
- Form and routes
- Powder For Solution · Nasogastric, Oral
- Schedule
- ETHICAL
- Authorised since
- 1986-12-31
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
No other medication authorised in Canada shares this active ingredient.
Health Canada groups products by their active ingredients. No other marketed product shares this one’s group, which usually means it is still the only authorised version — not that alternatives were hidden or missed.
Ontario Drug Benefit coverage
As of 31 July 2026Listed, not a benefit Part III
This product appears in Ontario’s Formulary/CDI but is not an ODB benefit — Ontario does not pay for it. It is listed so that a pharmacist can see which products are interchangeable with it, which is usually the case for an originator brand sitting beside its generics.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at Pd-4L Pk and will substitute one for another at a pharmacy counter in Ontario.
- Jamplyte 02378329Jamp Pharma Corporation
- Peglyte Powder 00777838Pendopharm Division of Pharmascience Inc
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Alimentary tract and metabolism
- ATC code
- A06AD65
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of A06AD65, see the WHO ATC/DDD Index.
Recalls and safety alerts
Recall matching is not available yet.
RxMonitor does not yet match Health Canada recalls to individual products — that arrives in a later release. Nothing on this page should be read as confirming that this medication has not been recalled.